Elisabetta Marino1, Luigina Graziosi2, Annibale Donini2. 1. General and Emergency Surgery, University of Perugia, Perugia, Italy elisabetta.marino1986@gmail.com. 2. General and Emergency Surgery, University of Perugia, Perugia, Italy.
Abstract
BACKGROUND/AIM: Neoadjuvant or perioperative chemotherapy is the standard treatment for locally advanced gastric cancer. However, in Eastern countries this is still debated. The aim of our study was to evaluate the survival impact of neoadjuvant chemotherapy. PATIENTS AND METHODS: A total of 60 patients who underwent preoperative chemotherapy were compared to patients with locally advanced gastric cancer that underwent upfront surgery. RESULTS: Median survival of the entire group curatively treated was 41 months with a median progression-free survival of 38 months. By excluding patients with stage IV disease from the neoadjuvant group, a statistically significant difference was reached both in terms of overall survival and disease-free survival. By subdividing patients according to pTNM stages, neoadjuvant patients showed better survival in stage I and II. CONCLUSION: Neoadjuvant chemotherapy could be an effective treatment for locally advanced disease. However, randomized studies are still needed to fully understand its role and identify patients that will benefit from it.
BACKGROUND/AIM: Neoadjuvant or perioperative chemotherapy is the standard treatment for locally advanced gastric cancer. However, in Eastern countries this is still debated. The aim of our study was to evaluate the survival impact of neoadjuvant chemotherapy. PATIENTS AND METHODS: A total of 60 patients who underwent preoperative chemotherapy were compared to patients with locally advanced gastric cancer that underwent upfront surgery. RESULTS: Median survival of the entire group curatively treated was 41 months with a median progression-free survival of 38 months. By excluding patients with stage IV disease from the neoadjuvant group, a statistically significant difference was reached both in terms of overall survival and disease-free survival. By subdividing patients according to pTNM stages, neoadjuvant patients showed better survival in stage I and II. CONCLUSION: Neoadjuvant chemotherapy could be an effective treatment for locally advanced disease. However, randomized studies are still needed to fully understand its role and identify patients that will benefit from it.
Authors: Kazumasa Fujitani; Jaffer A Ajani; Christopher H Crane; Barry W Feig; Peter W Pisters; Nora Janjan; Garrett L Walsh; Stephen G Swisher; Ara A Vaporciyan; David Rice; Angela Welch; Jackie Baker; Josephine Faust; Paul F Mansfield Journal: Ann Surg Oncol Date: 2007-03-08 Impact factor: 5.344
Authors: V Valenti; J L Hernandez-Lizoaín; M C Beorlegui; J A Diaz-Gozalez; F M Regueira; J J Rodriguez; A Viudez; I Sola; J A Cienfuegos Journal: J Surg Oncol Date: 2011-04-20 Impact factor: 3.454
Authors: T Yoshikawa; M Sasako; S Yamamoto; T Sano; H Imamura; K Fujitani; H Oshita; S Ito; Y Kawashima; N Fukushima Journal: Br J Surg Date: 2009-09 Impact factor: 6.939
Authors: Petra Ganschow; Lena Hofmann; Sebastian Stintzing; Volker Heinemann; Martin Angele; Jens Werner; Christoph Schulz Journal: J Gastrointest Surg Date: 2020-02-10 Impact factor: 3.452
Authors: Amir Zeide Charruf; Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; Andre Roncon Dias; Tiago Biachi de Castria; Bruno Zilberstein; Ivan Cecconelo; Ulysses Ribeiro Journal: J Surg Oncol Date: 2020-01-14 Impact factor: 3.454